RESEARCH TRIANGLE PARK – Animal health startup Resilient Biotics’ five-year progress is drawing big interest from investors.
Some 18 of them have put more than $7.1 million into the company, which has offices and a lab in RTP.
According to a securities filing signed by CEO and founder Christopher Belnap, the company doesn’t see the funding lasting more than a year.
The company’s lead product is designed to treat Bovine Respiratory Disease, according to the N.C. Biotechnology Center.
The focus of Resilient is “developing microbiome-derived, live biotherapeutics for animal health.”
And it’s relying on analytics to advance R&D.
“Resilient Biotics is utilizing big data analytics to design microbiome-based therapeutics and advanced screening methods for prevention and precision treatment of deadly infectious diseases,” the company says.
“Our goal is to provide more effective treatment strategies while reducing dependency on antibiotics.”
